Skip to content
City AM
Main navigation
Download free app
  • News
    • News
      • Latest Business News
      • Economics
      • Politics
      • Insurance
      • Square Mile and me
      • Tech
      • Legal
      • Banking
      • Property
      • Retail
      • Crypto
      • Transport
    • From our partners
      • AON
      • City of London BIDs
      • Central London Alliance CIC
      • Inside Saudi
      • London Stansted Airport
      • Tottenham Hotspur Stadium
    • Featured

      John Caudwell: Bezos gives billionaires a bad name

      Submit a story

      Tell us your story.

      Submit
  • Opinion
  • Sport
    • Latest Sports News
      • Sport
      • Sport Business
      • The Punter
    • From our partners
      • The Morning Briefing: SBS x City AM
      • Aramco Team Series
      • LIV Golf
    • Featured

      British and Irish Lions: Aussie pubs certain there’s enough Guinness

      Submit a story

      Tell us your story.

      Submit
  • Life&Style
    • Life&Style
      • Life&Style
      • Toast the City Awards
      • The Magazine
      • Travel
      • Culture
      • Motoring
      • Wellness
      • The RED BULLETiN
      • Do it with Shared Ownership
      • Media Speak Hub
    • Featured

      A day with London’s exclusive Auto Vivendi supercar club

      Submit a story

      Tell us your story.

      Submit
  • Personal Finance
  • City AM Events
  • Newsletters
  • Latest Paper
  • Sign In
  • Sign Out
  • My Account

pharma

  • Astrazeneca chief ‘wants to shift London listing to US’

    Markets

    The boss of Britain’s most valuable company, Astrazeneca, has reportedly voiced his preference to move the firm’s stock market listing to the United States. Sir Pascal Soriot, who has been at the helm of the pharma juggernaut since 2012, is said to have spoken privately about his desire to abandon the UK listing in favour [...]

  • GSK and Astrazeneca shares slump as Trump vows drug price cut

    pharma

    GSK and Astrazeneca shares fall as Trump announces drug price cuts in a new executive order.

  • GSK shares rise as FTSE 100 giant ‘well positioned’ for pharma tariffs

    pharma

    British drugmaker GSK insisted it was “well positioned” to respond to the impact of sector-specific tariffs amid widespread speculation President Donald Trump is set to target pharmaceutical imports with his tariff agenda. Trump voiced his desire to slap tariffs on pharma products in the “not too distant future”. He previously said: “We don’t make our [...]

  • As FTSE 100 pharma firms wait for a tariffs decision, what would drugs levies mean for consumers?

    April 22, 2025

    For FTSE 100 businesses navigating the shifting sands of Trump’s trade war, the uncertainty surrounding the tariffs has been almost as painful as the stock market shocks.  The pharmaceutical industry has been left in a particularly agonising limbo: free, for now, from the 10 per cent baseline import tax, but the US President keeps making [...]

  • It takes a village: Do we need to rethink our attitude to old age?

    April 10, 2025

    We’re living for longer than ever but the boom in the elderly population is a social and political time-bomb. Could ‘later life’ communities like Auriens be the answer to the old age crisis, asks Steve Dinneen I enter a grand lobby, all lofty ceilings, marquetry floors and art deco fittings. An effusive concierge in a natty [...]

  • Bionow Awards honour our greatest Innovators

    April 9, 2025  |  Sponsored

    The Bionow Awards are given to honour those most deserving for their ingenuity and dedication, distinguishing them from their competitors and proving them worthy of recognition.  With a prestigious history of more than 20 years, the awards have become the leading life sciences accolades in the UK; highlighting the achievements of the sector, shining a [...]

  • Hikma’s profit jumps as demand for generic medicines booms

    February 26, 2025

    Hikma Pharmaceuticals reported a strong financial performance for 2024, with revenue rising nine per cent to $3.13bn (£2.47bn) and operating profit up 67 per cent to $612m (£483m). Profit attributable to shareholders nearly doubled, reaching $359m (£284m), while earnings per share rose 88 per cent. The multinational pharmaceutical company that develops, manufactures, and markets a [...]

  • FTSE 100 giant GSK eyes more than £40bn in sales by 2031

    February 5, 2025

    Pharmaceutical giant GSK has hiked its 2031 sales forecast to more than £40bn, up from £38bn, after reporting better than forecast fourth quarter earnings. The London-listed pharma giant reported core earnings per share of 23.2p for the quarter, a drop of around 20 per cent year-on-year. However, this was greater than the 19p that analysts [...]

  • Astrazeneca boosts cardiovascular pipeline with licensing deal

    October 7, 2024

    Astrazeneca has struck a licensing agreement worth up to $2bn (£1.5bn) with China’s CPSC Pharmaceutical Group to develop a new cardiovascular drug, the company announced on Monday. The Anglo-Swedish pharmaceutical giant will pay $100m (£76.5) upfront, with additional milestone payments of up to $1.9bn (£1.4bn), to licence a preclinical small molecule aimed at treating dyslipidemia. [...]

Trending Articles

  • Meet the Self-Mades: the high earners who aren't investing

  • The 17 best pubs in the City of London – picked by experts

  • £100K isn't a big salary - and we need to talk about it

  • Mike Ashley tightens grip on Hugo Boss amid dividend demand

Subscribe

Subscribe to the City AM newsletter to have our top stories delivered directly to your inbox.

Subscribe
  • About us
  • Careers
  • Terms & Conditions
  • Privacy Policy
  • Cookie Policy
  • News
  • Markets & Economics
  • Opinion
  • Life&Style
  • Personal Finance
  • Got a story?
  • City AM Events
  • The Punter
  • City AM Curated
  • Casino

Follow us for breaking news and latest updates

  • Facebook
  • X
  • Instagram
  • LinkedIn
  • Newsletters
  • Advertising
  • About
  • Tickets
Copyright 2025 City AM Limited